Press Releases

June 20, 2019
New Initiative to Create Awareness and Understanding of Life-Threatening Pediatric Liver Disease  Announced new PFIC Voices website, www.PFICvoices.com BOSTON , June 20, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing
May 29, 2019
BOSTON , May 29, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the following investor conferences
May 9, 2019
Odevixibat Phase 3 PEDFIC 1 PFIC trial continues to enroll as planned Initiation of additional cohort of PFIC patients in PEDFIC 2 extension trial announced Odevixibat pivotal trial in biliary atresia on track to begin H2 2019 IND cleared to initiate elobixibat Phase 2 trial in NASH Q2 2019
April 1, 2019
BOSTON , April 01, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will present at the following investor conferences in April: H.C. Wainwright & Co.